Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
OraSure Technologies announced second quarter 2026 financial results with $30.6 million in revenue, representing sequential growth and slight year-over-year decline. The company achieved FDA clearances for innovative diagnostic products, including the Colli-PeeDx urine collection device and an updated Ebola rapid test, aligning with their strategy …
Pacific Biosciences of California, Inc. (PacBio) announced its financial results for Q2 2026, reporting total revenue of $39.0 million, largely steady compared to the prior year quarter. The company began a global commercial rollout of its SPRQ-Nx chemistry, achieving a $345 list price per genome sequencing and highlighting several scientific publi…
Datadog, a leading AI-driven observability and security platform, announced that its management will present at three major investor conferences in August and September 2026. These presentations offer opportunities for the company to communicate its growth prospects and technology advancements to investors and analysts, with live webcasts and repla…
Trupanion, Inc., a leading provider of medical insurance for cats and dogs, reported strong financial results for the second quarter of 2026, including 11% total revenue growth and a 14% increase in subscription revenue. The company improved adjusted EBITDA and free cash flow compared to the previous year. Trupanion also announced an extraordinary …
Satellogic Inc. reported a substantial 259% year-over-year revenue increase to $15.9 million for Q2 2026, marking the company's first quarter of positive operating income ($0.3 million) and positive adjusted EBITDA ($2.8 million). The company strengthened its capital position with $112.8 million cash on hand and executed key contracts in sovereign …
Runway Growth Finance Corp. announced a third quarter 2026 cash dividend of $0.33 per share, with key dates set for August 2026. The company intends to distribute substantially all available earnings on a quarterly basis, maintaining its status as a business development company focusing on providing capital solutions to late- and growth-stage compa…
Phillips Edison & Company, a leading owner and operator of grocery-anchored neighborhood shopping centers, declared a monthly dividend of $0.1083 per share payable on September 1, 2026. This dividend reflects the company's strong operational performance and steady cash flow from its retail real estate portfolio.
Remitly Global, Inc. reported record second quarter 2026 financial results, surpassing 10 million active customers for the first time, with a 27% increase in send volume and 20% revenue growth year over year. The company achieved $205.9 million in net income, boosted by a $140.6 million tax benefit, and a 79% increase in adjusted EBITDA. Remitly ra…
Encore Capital Group announced its second quarter 2026 financial results, highlighting record U.S. portfolio purchases of $372 million and global collections reaching a record $737 million, a 13% year-over-year increase. Despite absorbing $1.00 per share in refinancing costs related to a $1 billion debt refinancing, the company delivered earnings p…
LifeVantage Corporation named Terrence Moorehead as its new President and CEO. Moorehead brings over 25 years of leadership experience in consumer wellness and digital transformation, previously leading Nature's Sunshine Products through successful brand modernization and growth. The company aims to leverage his expertise to accelerate growth and s…
TELA Bio, a Nasdaq-listed medical technology company, announced inducement grants consisting of stock options and restricted stock units to its newly-hired CEO Heather Getz and 11 new employees. The grants are made under Nasdaq listing rule inducement exception as part of employment compensation with specified exercise prices and vesting schedules.
Hudson Technologies reported second quarter 2026 revenues of $78.3 million, an 8% increase year-over-year driven by a 12% sales volume growth offset by 6% lower selling prices due to refrigerant market conditions. The company restored operations quickly after a tornado-impacted facility disruption, announced a partnership with Icorium to scale adva…
ThredUp Inc. announced its Q2 2026 results, achieving record quarterly revenue of $90.8 million, up 17% year-over-year, and active buyers increasing 21%. Gross margin improved slightly to 79.9%, and adjusted EBITDA reached $4.8 million. Despite strong quarterly performance, the company lowered its H2 2026 guidance due to economic uncertainty impact…
RxSight, Inc. reported Q2 2026 revenue of $33.7 million, including $6.5 million from its strategic collaboration with Alcon, alongside a 19% decline in product sales reflecting market pressures. The company appointed Aziz Mottiwala as CEO and initiated development of next-generation light adjustable lens technology but withdrew its 2026 financial g…
Cytek Biosciences reported a 6% year-over-year revenue increase to $48.1 million for Q2 2026, driven by strong instrument sales growth in the US and China and expanding recurring revenue from services and reagents. The company launched new products including Cytek Borealis and Aurora Evo with enhanced features. Despite the revenue growth and improv…
ARC Group Securities Acquisition I, a Cayman Islands exempted blank check company, announced the closing of its $105 million IPO with 10.5 million units priced at $10 each. The units began trading on Nasdaq under the ticker FJDIU. Each unit consists of one Class A ordinary share, one redeemable warrant, and one right to receive a fractional share a…
EverCommerce Inc. announced its Q2 2026 financial results with revenue up 2.7% year-over-year to $152 million and net income from continuing operations increasing to $9.7 million. Adjusted EBITDA was slightly lower than the previous year at $44.5 million but exceeded the upper end of guidance. The company repurchased 1.4 million shares and updated …
Nyxoah SA reported robust financial and operating results for Q2 and H1 2026, driven by successful U.S. commercial execution post FDA approval of its lead product, the Genio system for treating obstructive sleep apnea. The company achieved 22% sequential revenue growth in the U.S. for Q2 and secured $110 million in financing to expand its commercia…
Biomea Fusion reported continued progress in its clinical programs targeting diabetes and obesity, including ongoing enrollment in Phase II trials for icovamenib in Type 2 diabetes and promising durability data in Type 1 diabetes. The company also advanced its Phase I trial for the obesity candidate BMF-650 and initiated a research collaboration fo…
Sight Sciences delivered significant growth in Q2 2026 with revenues increasing 20% year-over-year. Interventional Dry Eye revenues surged 704% driven by higher volumes and selling prices. The company achieved strong gross margins, improved cash usage, and decreased operating expenses, leading to a 63% reduction in net loss compared to the prior ye…
Nasdaq has published its trading volume statistics for July 2026 on its Investor Relations website, providing transparency on market activity. The data highlights ongoing market operations through Nasdaq's technology platform which continues to support global financial markets.
ADMA Biologics delivered a strong second quarter in 2026 with total revenue up 2% year-over-year to $124.4 million, powered by a 24% increase in ASCENIV revenues. The company's flagship product, ASCENIV, showed accelerated demand and utilization, while BIVIGAM revenue stabilized after prior declines. GAAP net income grew 11% year-over-year to $37.8…
Vaxcyte reported its Q2 2026 financial results, highlighting progress in its VAX-31 pneumococcal conjugate vaccine Phase 3 program with topline data from the OPUS-1 trial expected by Q4 2026 and additional OPUS-2 and OPUS-3 results in H1 2027. The company is also advancing its early-stage pipeline including VAX-A1 for Group A Streptococcus in Phase…
Crane NXT, Co. (NYSE: CXT) announced robust financial results for Q2 2026, including a 22% year-over-year increase in sales to $493 million and a 13% rise in adjusted earnings per share (EPS) to $1.10. The company raised its full-year adjusted EPS guidance to a range of $4.22 to $4.42, reflecting confidence in ongoing momentum and successful integr…
Barrett Business Services, Inc. (NASDAQ: BBSI) reported Q2 2026 revenues increased 4% to $319.3 million with gross billings rising 3%. Despite revenue growth driven by new client additions and higher billings per employee, net income declined to $12.9 million ($0.52 per diluted share) compared to $18.5 million ($0.70 per diluted share) last year, m…
